195 related articles for article (PubMed ID: 29304535)
1. Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.
Groeneveld DJ; Sanders YV; Adelmeijer J; Mauser-Bunschoten EP; van der Bom JG; Cnossen MH; Fijnvandraat K; Laros-van Gorkom BAP; Meijer K; Lisman T; Eikenboom J; Leebeek FWG
Thromb Haemost; 2018 Jan; 118(1):152-160. PubMed ID: 29304535
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor regulation of blood vessel formation.
Randi AM; Smith KE; Castaman G
Blood; 2018 Jul; 132(2):132-140. PubMed ID: 29866817
[TBL] [Abstract][Full Text] [Related]
3. Endothelial von Willebrand factor regulates angiogenesis.
Starke RD; Ferraro F; Paschalaki KE; Dryden NH; McKinnon TA; Sutton RE; Payne EM; Haskard DO; Hughes AD; Cutler DF; Laffan MA; Randi AM
Blood; 2011 Jan; 117(3):1071-80. PubMed ID: 21048155
[TBL] [Abstract][Full Text] [Related]
4. Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis.
Gritti G; Cortelezzi A; Bucciarelli P; Rezzonico F; Lonati S; La Marca S; Silvestris I; Federici AB
Am J Hematol; 2011 Aug; 86(8):650-6. PubMed ID: 21630316
[TBL] [Abstract][Full Text] [Related]
5. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention.
Lim HS; Blann AD; Chong AY; Freestone B; Lip GY
Diabetes Care; 2004 Dec; 27(12):2918-24. PubMed ID: 15562207
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor and angiogenesis: basic and applied issues.
Randi AM; Laffan MA
J Thromb Haemost; 2017 Jan; 15(1):13-20. PubMed ID: 27778439
[TBL] [Abstract][Full Text] [Related]
7. Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis.
Cossutta M; Darche M; Carpentier G; Houppe C; Ponzo M; Raineri F; Vallée B; Gilles ME; Villain D; Picard E; Casari C; Denis C; Paques M; Courty J; Cascone I
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1843-1858. PubMed ID: 31315435
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand disease and Weibel-Palade bodies.
Wang JW; Eikenboom J
Hamostaseologie; 2010 Aug; 30(3):150-5. PubMed ID: 20680229
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic characteristics of blood outgrowth endothelial cells from patients with von Willebrand disease.
Groeneveld DJ; van Bekkum T; Dirven RJ; Wang JW; Voorberg J; Reitsma PH; Eikenboom J
J Thromb Haemost; 2015 Oct; 13(10):1854-66. PubMed ID: 26270243
[TBL] [Abstract][Full Text] [Related]
10. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.
Haberichter SL; Merricks EP; Fahs SA; Christopherson PA; Nichols TC; Montgomery RR
Blood; 2005 Jan; 105(1):145-52. PubMed ID: 15331450
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
12. Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.
Castaman G; Giacomelli SH; Jacobi PM; Obser T; Budde U; Rodeghiero F; Schneppenheim R; Haberichter SL
J Thromb Haemost; 2012 May; 10(5):951-8. PubMed ID: 22429825
[TBL] [Abstract][Full Text] [Related]
13. Complement promotes endothelial von Willebrand factor and angiopoietin-2 release in obstructive sleep apnea.
Gao S; Emin M; Thoma T; Pastellas K; Castagna F; Shah R; Jimenez A; Patel N; Wei Y; Jelic S
Sleep; 2021 Apr; 44(4):. PubMed ID: 33351148
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor binds to angiopoietin-2 within endothelial cells and after release from Weibel-Palade bodies.
Mobayen G; Smith K; Ediriwickrema K; Starke RD; Solomonidis EG; Laffan MA; Randi AM; McKinnon TAJ
J Thromb Haemost; 2023 Jul; 21(7):1802-1812. PubMed ID: 37011710
[TBL] [Abstract][Full Text] [Related]
16. Storage and secretion of naturally occurring von Willebrand factor A domain variants.
Groeneveld DJ; Wang JW; Mourik MJ; Dirven RJ; Valentijn KM; Voorberg J; Reitsma PH; Eikenboom J
Br J Haematol; 2014 Nov; 167(4):529-40. PubMed ID: 25103891
[TBL] [Abstract][Full Text] [Related]
17. Clusterin knockdown has effects on intracellular and secreted von Willebrand factor in human umbilical vein endothelial cells.
Cox AA; Liu A; Ng CJ
PLoS One; 2024; 19(2):e0298133. PubMed ID: 38363768
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.
Starke RD; Paschalaki KE; Dyer CE; Harrison-Lavoie KJ; Cutler JA; McKinnon TA; Millar CM; Cutler DF; Laffan MA; Randi AM
Blood; 2013 Apr; 121(14):2773-84. PubMed ID: 23355534
[TBL] [Abstract][Full Text] [Related]
19. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment.
Mohan JS; Lip PL; Blann AD; Bareford D; Lip GY
Br J Ophthalmol; 2005 Jul; 89(7):815-9. PubMed ID: 15965157
[TBL] [Abstract][Full Text] [Related]
20. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
